Keyphrases
Advanced HIV Disease
14%
AIDS/HIV
19%
Amphotericin B
28%
Antigen Screening
21%
C-reactive Protein
13%
Central Nervous System
13%
Cerebrospinal Fluid
31%
Cerebrospinal Fluid Culture
8%
Clinical Trials
19%
Confidence Interval
11%
COVID-19
56%
Cryptococcal Antigen
42%
Cryptococcal Antigenemia
30%
Cryptococcal Meningitis
100%
Cryptococcosis
17%
Cryptococcus
13%
Cytomegalovirus
15%
Cytomegalovirus Viremia
26%
Early Fungicidal Activity
8%
Fluconazole
16%
HIV Patients
13%
HIV-associated
10%
HIV-infected Adults
13%
Hydroxychloroquine
36%
Increased Mortality
9%
Lateral Flow Assay
12%
Lipids
8%
Meningitis
34%
Meningitis Diagnosis
13%
Minimum Inhibitory Concentration
11%
Mortality Factors
8%
Mycobacterium Tuberculosis (M. tb)
9%
Nanocrystals
8%
Non-HIV Cryptococcal Meningitis
8%
People Living with HIV (PLHIV)
16%
Placebo
10%
Pre-exposure Prophylaxis (PrEP)
22%
Randomized Clinical Trial
25%
Randomized Trial
20%
Sub-Saharan Africa
12%
Titer
12%
Tuberculosis
11%
Tuberculosis Diagnosis
15%
Tuberculosis Meningitis
8%
Uganda
22%
Ugandan
24%
United States
9%
Virus Diseases
14%
Web-based
10%
Xpert MTB
13%
Medicine and Dentistry
Amphotericin
8%
Amphotericin B
12%
Antifungal Agent
6%
Antifungal Susceptibility
6%
Antigen
21%
C Reactive Protein
6%
Central Nervous System
6%
Cerebrospinal Fluid
20%
Cerebrospinal Fluid Culture
8%
Chloroquine
6%
Clinical Trial
15%
Cluster Randomized Trial
6%
COVID-19
36%
Cryptococcal Meningitis
88%
Cryptococcosis
14%
Cytomegalovirus
26%
Diagnosis
18%
Diagnostic Performance
8%
Disease
29%
Dried Blood Spot
6%
Extrapulmonary Tuberculosis
5%
Fluconazole
10%
Flucytosine
6%
Human Immunodeficiency Virus
84%
Hydroxychloroquine
16%
Hyponatremia
6%
Immune Reconstitution Inflammatory Syndrome
6%
Infection
16%
Intracranial Pressure
5%
Lateral Flow Assay
14%
Lipoarabinomannan
6%
Meningitis
35%
Mental Health
5%
Mycobacterium Tuberculosis
6%
Outpatient
29%
Placebo
8%
Post-Exposure Prophylaxis
6%
Prevalence
5%
Puerperium
6%
Randomized Clinical Trial
16%
Randomized Controlled Trial
9%
Recurrent Disease
6%
Screening
7%
Sertraline
6%
Severe Acute Respiratory Syndrome Coronavirus 2
27%
Symptom
21%
Systematic Review
6%
Tuberculous Meningitis
6%
Viremia
26%
Virus Infection
16%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
12%
Amphotericin
15%
Amphotericin B
21%
Amphotericin B Deoxycholate
6%
Antifungal Agent
6%
Bacteremia
6%
C Reactive Protein
13%
Chloroquine
6%
Clinical Trial
24%
Coronavirinae
41%
Cryptococcal Meningitis
43%
Cryptococcosis
5%
Cryptococcus neoformans
6%
Cytomegalovirus
13%
Disease
56%
Filobasidiella
15%
Fluconazole
11%
Flucytosine
8%
HIV
36%
Hydroxychloroquine
39%
Infection
19%
Lipoarabinomannan
6%
Meningitis
15%
Minimum Inhibitory Concentration
10%
Placebo
16%
Randomized Clinical Trial
22%
Randomized Controlled Trial
9%
SARS Coronavirus
23%
Sertraline
6%
Symptom
16%
Tolerability
6%
Tuberculous Meningitis
6%
Viremia
13%
Virus Infection
10%
